The Thieno[3,2-c]pyridine and Furo[3,2-c]pyridine Rings: New Pharmacophores with Potential Antipsychotic Activity

Journal of Medicinal Chemistry

Volumn 32, Issue 6, 1989, Pages 1147-1156

  New, James S ^a   Christopher, William L ^a   Yevich, Joseph P ^a   Butler, Rhett ^a   Schlemmer, R Francis ^b   Vandermaelen, Cam P ^a   Cipollina, Joseph A ^a  

^a BRISTOL MYERS SQUIBB   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [4 [4 (FURO[3,2 C] PYRIDIN 4 YL) 1 PIPERAZINYL]BUTYL] 3,5 MORPHOLINEDIONE; 4,4 DIMETHYL 1 [4 [4 (THIENO[3,2 C]PYRIDIN 4 YL) 1 PIPERAZINYL]BUTYL] 2,6 PIPERIDINEDIONE; CHLORPROMAZINE; CLOZAPINE; DOPAMINE 2 RECEPTOR; FURO[3,2 C]PYRIDINE DERIVATIVE; RADIOISOTOPE; SEROTONIN RECEPTOR; THIENO[3,2 C]PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; BEHAVIOR; CELL CULTURE; DRUG SYNTHESIS; INFRARED SPECTROPHOTOMETRY; INTRAVENOUS DRUG ADMINISTRATION; MONKEY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; ORAL DRUG ADMINISTRATION; PSYCHOLOGICAL ASPECT; PSYCHOSIS; RAT;

AMPHETAMINES; ANIMAL; AVOIDANCE LEARNING; BINDING, COMPETITIVE; CATALEPSY; CHEMISTRY; COMPARATIVE STUDY; DIOXANES; FEMALE; FURANS; MACACA; MALE; MICE; MOLECULAR STRUCTURE; MOTOR ACTIVITY; PIPERAZINES; PSYCHOSES, SUBSTANCE-INDUCED; PSYCHOTIC DISORDERS; PYRIDINES; RATS; RATS, INBRED STRAINS; RECEPTORS, ADRENERGIC, ALPHA; RECEPTORS, DOPAMINE; RECEPTORS, SEROTONIN; SPIPERONE; STEREOTYPED BEHAVIOR; STRUCTURE-ACTIVITY RELATIONSHIP; THIOPHENES;

EID: 0024375222     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm00126a002     Document Type: Article

References (26)

1. Yevich, J. P.; Temple, D. L., Jr.; New, J. S.; Taylor, D. P.; Riblet, L. A. J. Med. Chem. 1983, 26, 194.
2. New, J. S.; Yevich, J. P.; Eison, M. S.; Taylor, D. P.; Eison, A. S.; Riblet, L. A.; Vandermaelen, C. P.; Temple, D. L., Jr. J. Med. Chem. 1986, 29, 1476.
3. Yevich, J. P.; New, J. S.; Smith, D. W.; Lobeck, W. G.; Catt, J. D.; Minielli, J. L.; Eison, M. S.; Taylor, D. P.; Riblet, L. A.; Temple, D. L., Jr. J. Med. Chem. 1986, 29, 359.
4. New, J. S.; Yevich, J. P.; Temple, D. L., Jr.; New, K. B.; Gross, S. M.; Schlemmer, R. F., Jr.; Eison, M. S.; Taylor, D. P.; Riblet, L. A. J. Med. Chem. 1988, 31, 618.
5. Eloy, F.; Dervckere. A. Helv. Chim. Acta 1970. 53. 645.
6. Eloy, F.; Deryckere, A. J. Heterocycl. Chem. 1971, 8, 57.
7. Elov. F.; Dervckere. A. Bull. Soc. Chim. Belges. 1970. 79. 301.
8. Bisagni, E.; Bourzat, J. D.; André-Louisfert, J. Tetrahedron 1970, 26, 2087.
9. Costall, B.; Naylor, R. J.; Nohvia, V. Eur. J. Pharmacol. 1978, 50.,39.
10. Yocca, F. D.; Yevich, J. P.; New, J. S. Drugs Future 1987, 12, 752.
11. Lal, H.; Fielding, S.; Eds. Psychopharmacology of Clonidine; Alan R. Liss: New York, 1981.
12. Henry, D. J.; White, F. J. Drug. Dev. Res. 1988, 12, 211.
13. Schlemmer, R. F., Jr.; Davis, J. M. Pharmacol. Biochem. Behav. 1981, 14 (Suppl 1), 95.
14. Schlemmer, R. F., Jr.; Davis, J. M. In Ethopharmacology: Primate Models of Neuropsychiatric Disorders; Miczek, K. A., Ed.; Alan R. Liss: New York, 1983; pp 33–78.
15. Temple, D. L., Jr.; Yeager, R. E. U. S. Patent 4,456,756, 1984.
16. Temple, D. L., Jr.; Yevich, J. P. U. S. Patent 4,361,565, 1982.
17. Temple, D. L., Jr.; Yevich, J. P. U. S. Patent 4,411,901, 1983.
18. New, J. S.; Yevich, J. P. U. S. Patent 4,677,104, 1987.
19. Peroutka, S. J. Brain Res. 1985, 344, 167.
20. VanderMaelen, C. P.; Matheson, G. K.; Wilderman, R. C.; Patterson, L. A. Eur. J. Pharmacol. 1986, 129, 123.
21. Cedarbaum, J. M.; Aghajanian, G. K. Eur. J. Pharmacol. 1977, 44, 375.
22. Guynet, P. G.; Aghajanian, G. K. Brain Res. 1978, 150, 69.
23. White, J. F.; Wang, R. Y. Science 1983, 221, 1054.
24. Costall, B.; Fortune, D. H.; Naylor, R. J.; Nohria, V. Eur. J. Pharmacol. 1980, 66, 207.
25. Costall, B.; Eniojukan, J. F.; Naylor, R. J. Eur. J. Pharmacol. 1983, 96, 201.
26. Protais, P.; Bonnet, J. J.; Constentin, J.; Schwartz, J. C. Nauyn-Schmiedberg's Arch. Pharmacol. 1984, 325, 93.